{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:16:10Z","timestamp":1785521770107,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pharming Healthcare, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12325-026-03625-0","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T08:06:25Z","timestamp":1779264385000},"page":"3506-3520","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Post Hoc Analysis of Recombinant C1 Inhibitor Clinical Data Using Contemporary Endpoints for Hereditary Angioedema"],"prefix":"10.1007","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct00225147","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01188564","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00262301","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Marc A.","family":"Riedl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihal","family":"Narsipur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffi","family":"Tachdjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Relan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Kilvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketsia","family":"Habimana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Roskell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Gough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Henry","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"issue":"1","key":"3625_CR1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","volume":"9","author":"PJ Busse","year":"2021","unstructured":"Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-50.e3.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"3625_CR2","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jaip.2014.12.013","volume":"3","author":"HH Li","year":"2015","unstructured":"Li HH, Moldovan D, Bernstein JA, Reshef A, Porebski G, Stobiecki M, et al. Recombinant human-C1 inhibitor is effective and safe for repeat hereditary angioedema attacks. J Allergy Clin Immunol Pract. 2015;3(3):417\u201323.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"3625_CR3","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2500\/aap.2010.31.3394","volume":"31","author":"WR Lumry","year":"2010","unstructured":"Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc. 2010;31(5):407\u201314.","journal-title":"Allergy Asthma Proc"},{"issue":"1","key":"3625_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-022-02360-3","volume":"17","author":"M Jean-Baptiste","year":"2022","unstructured":"Jean-Baptiste M, Itzler R, Prusty S, Supina D, Martin ML. The symptom experience of hereditary angioedema (HAE) patients beyond HAE attacks: literature review and clinician interviews. Orphanet J Rare Dis. 2022;17(1):1\u201312.","journal-title":"Orphanet J Rare Dis"},{"key":"3625_CR5","unstructured":"Berinert. Prescribing information. CSL Behring; 2021."},{"key":"3625_CR6","unstructured":"Ekterly. Prescribing information. KalVista Pharmaceuticals, Inc; 2025."},{"key":"3625_CR7","unstructured":"Firazyr. Prescribing information. Takeda Pharmaceuticals America, Inc; 2024."},{"key":"3625_CR8","unstructured":"Kalbitor. Prescribing information. Takeda Pharmaceuticals U.S.A., Inc; 2025."},{"key":"3625_CR9","unstructured":"Ruconest. Prescribing information. Pharming Healthcare Inc; 2025."},{"issue":"6","key":"3625_CR10","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1056\/NEJMoa0906393","volume":"363","author":"M Cicardi","year":"2010","unstructured":"Cicardi M, Banerji A, Bracho F, Malbran A, Rosenkranz B, Riedl M, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010;363(6):532\u201341.","journal-title":"N Engl J Med"},{"issue":"6","key":"3625_CR11","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa0905079","volume":"363","author":"M Cicardi","year":"2010","unstructured":"Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, Campion M, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010;363(6):523\u201331.","journal-title":"N Engl J Med"},{"issue":"4","key":"3625_CR12","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.jaci.2009.07.017","volume":"124","author":"TJ Craig","year":"2009","unstructured":"Craig TJ, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz D, Obtulowicz K, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009;124(4):801\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"3625_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.anai.2010.04.012","volume":"104","author":"RJ Levy","year":"2010","unstructured":"Levy RJ, Lumry WR, McNeil DL, Li HH, Campion M, Horn PT, et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104(6):523\u20139.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"3625_CR14","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.anai.2011.08.015","volume":"107","author":"WR Lumry","year":"2011","unstructured":"Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, Moldovan D, et al. Randomized placebo-controlled trial of the bradykinin B(2) receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol. 2011;107(6):529\u201337.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"3625_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.anai.2013.12.004","volume":"112","author":"MA Riedl","year":"2014","unstructured":"Riedl MA, Bernstein JA, Li H, Reshef A, Lumry W, Moldovan D, et al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol. 2014;112(2):163-9.e1.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"3625_CR16","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jaci.2010.07.021","volume":"126","author":"B Zuraw","year":"2010","unstructured":"Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Relan A, Visscher S, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol. 2010;126(4):821-7.e14.","journal-title":"J Allergy Clin Immunol"},{"key":"3625_CR17","unstructured":"Study of oral deucrictibant soft capsule for on-demand treatment of angioedema attacks in adolescents and adults with hereditary angioedema (RAPIDe-3). ClinicalTrials.gov identifier: NCT06343779. Updated November 21, 2025. Accessed December 24, 2025. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06343779."},{"issue":"1","key":"3625_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa2314192","volume":"391","author":"MA Riedl","year":"2024","unstructured":"Riedl MA, Farkas H, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Psarros F, Soteres DF, Staevska M, et al. Oral sebetralstat for on-demand treatment of hereditary angioedema attacks. N Engl J Med. 2024;391(1):32\u201343.","journal-title":"N Engl J Med"},{"issue":"1","key":"3625_CR19","first-page":"1","volume":"5","author":"S Amatya","year":"2025","unstructured":"Amatya S, Edgerton D, Sage E. Guidance for eCOA development in clinical trials. J Soc Clin Data Manag. 2025;5(1):1\u201323.","journal-title":"J Soc Clin Data Manag"},{"key":"3625_CR20","unstructured":"Recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema. ClinicalTrials.gov identifier: NCT00225147. Updated February 22, 2013. Accessed June 2025. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT00225147."},{"key":"3625_CR21","unstructured":"Recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema. ClinicalTrials.gov identifier: NCT00262301. Updated October 2, 2012. Accessed June 2025. Available at: https:\/\/clinicaltrials.gov\/study\/NCT00262301."},{"key":"3625_CR22","doi-asserted-by":"crossref","unstructured":"Manning ME, Narsipur N, Anderson J, Smith A, Johnson N, Evans C, et al. Mapping patient-reported outcome measures across clinical trials in hereditary angioedema (HAE). Poster presented at: American College of Allergy, Asthma, and Immunology (ACAAI) 2025 Annual Scientific Meeting; November 6\u201310, 2025; Orlando, FL.","DOI":"10.1016\/j.anai.2025.08.134"},{"key":"3625_CR23","unstructured":"Mapi Research Trust ePROVIDE. Patient global impressions scale - change, improvement, severity (PGI-C, PGI-I, PGI-S). Accessed January 8, 2025. Available at: https:\/\/eprovide.mapi-trust.org\/instruments\/patient-global-impressions-scale-change-improvement-severity."},{"key":"3625_CR24","unstructured":"Riedl MA, Li PH, Adatia A, Cancian M, Stobiecki M, Valerieva A, et al. Oral deucrictibant immediate-release capsule in treatment of hereditary angioedema attacks: results of the phase 3 RAPIDe-3 study. Poster presented at: the American Academy of Allergy, Asthma & Immunology 2026 Annual Meeting; February 27-March 2, 2026; Philadelphia, PA."},{"issue":"6","key":"3625_CR25","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","volume":"15","author":"JE Signorovitch","year":"2012","unstructured":"Signorovitch JE, Sikirica V, Erder MH, Xie J, Lu M, Hodgkins PS, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940\u20137.","journal-title":"Value Health"},{"key":"3625_CR26","doi-asserted-by":"crossref","unstructured":"Davis-Lorton M, Tachdjian R, Saharia P, Jindal S, Park N, Harper JR, et al. Systematic literature review of recombinant human C1 esterase inhibitor (rhC1-INH) and other products for the on-demand treatment of hereditary angioedema attacks. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2025 Annual Meeting; May 13\u201316, 2025; Montreal, QC, Canada.","DOI":"10.1016\/j.jval.2025.04.116"},{"issue":"9","key":"3625_CR27","doi-asserted-by":"publisher","first-page":"937.e17","DOI":"10.1016\/j.amjmed.2011.12.016","volume":"125","author":"A Kusuma","year":"2012","unstructured":"Kusuma A, Relan A, Knulst AC, Moldovan D, Zuraw B, Cicardi M, et al. Clinical impact of peripheral attacks in hereditary angioedema patients. Am J Med. 2012;125(9):937.e17-24.","journal-title":"Am J Med"},{"issue":"7","key":"3625_CR28","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1111\/all.15214","volume":"77","author":"M Maurer","year":"2022","unstructured":"Maurer M, Magerl M, Betschel S, Aberer W, Ansotegui IJ, Ayg\u00f6ren-P\u00fcrs\u00fcn E, et al. The international WAO\/EAACI guideline for the management of hereditary angioedema\u2014the 2021 revision and update. Allergy. 2022;77(7):1961\u201390.","journal-title":"Allergy"},{"issue":"4","key":"3625_CR29","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.iac.2013.07.006","volume":"33","author":"L Bouillet","year":"2013","unstructured":"Bouillet L, Gompel A. Hereditary angioedema in women: specific challenges. Immunol Allergy Clin North Am. 2013;33(4):505\u201311.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"1","key":"3625_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13223-025-00955-6","volume":"21","author":"HH Li","year":"2025","unstructured":"Li HH, Ayg\u00f6ren-P\u00fcrs\u00fcn E, Magerl M, Craig TJ, Manning ME, Hummel N, et al. Indirect treatment comparison of oral sebetralstat and intravenous recombinant human C1 esterase inhibitor for on-demand treatment of hereditary angioedema attacks. Allergy Asthma Clin Immunol. 2025;21(1):1\u201311.","journal-title":"Allergy Asthma Clin Immunol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03625-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03625-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03625-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:06:44Z","timestamp":1785517604000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03625-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3625"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03625-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Marc A. Riedl has received research or consulting support from or provided speaker presentations for Astria Therapeutics, BioCryst Pharmaceuticals, Inc, BioMarin Pharmaceutical, Celldex Therapeutics, CSL Behring, Cycle Pharma, Grifols, Intellia, Ionis Pharmaceuticals, Inc, KalVista Pharmaceuticals, Novartis, Pharming Healthcare, Inc., Pharvaris, Sanofi-Regeneron, and Takeda. Douglas Jones is a consultant for Pharming Healthcare, Inc., KalVista Pharmaceuticals, Takeda Pharmaceutical Company Limited, CSL Behring, BioCryst Pharmaceuticals, Inc, and Pharvaris. Raffi Tachdjian has received research or consulting support from Astria Therapeutics, BioCryst Pharmaceuticals, Inc, CSL Behring, Ionis Pharmaceuticals, Inc, Intellia, KalVista Pharmaceuticals, Pharming Healthcare, Inc., Pharvaris, and Takeda Pharmaceutical Company Limited; and provided speaker presentations for ARS Pharmaceuticals, AstraZeneca, BioCryst Pharmaceuticals, Inc, CSL Behring, Grifols, GSK, Pharming Healthcare, Inc., Sanofi-Regeneron, and Takeda Pharmaceutical Company Limited. Hannah Kilvert, Emily Aiello, Ketsia Habimana, Neil Roskell, and Adam Gough are employees of Lumanity, which received consulting fees from Pharming Healthcare, Inc. H. Henry Li has received research or consulting support from or provided speaker presentations for CSL Behring, BioCryst Pharmaceuticals, Pharvaris, Argo Biopharma, KalVista Pharmaceuticals, Takeda Pharmaceutical Company Limited, Intellia Therapeutics, Pharming Healthcare, Inc., and Ionis Pharmaceuticals, Inc. Nihal Narsipur, Anurag Relan, Joseph R. Harper, and Amanda Harrington are employees of Pharming Healthcare, Inc.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a post hoc analysis of previously conducted studies that were performed in accordance with the Helsinki Declaration of 1964 and its later amendments and does not contain any new studies with human participants performed by any of the authors, therefore ethics committee approval was not required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}